NCT05177237View on ClinicalTrials.gov

Endostar Combined With Corticosteroid for Treatment of Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 28, 2021

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2025

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

Endostar

Endostar: 210 mg (14 PCS) continuous infusion for 168h, Q3W, 4 cycles. Methylprednisolone: 80mg intravenously, once daily, for 3-5 days, gradually reduced to 10mg/ day oral maintenance dose.

Trial Locations (1)

330000

RECRUITING

Xiaochang Gong, Nanchang

All Listed Sponsors
lead

Jiangxi Provincial Cancer Hospital

OTHER